NCT03301454 2026-03-18
E-DIS2
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
213 trialsNCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT07205731 2026-03-05
SAFE ESO
University Hospital, Clermont-Ferrand
Phase 2 Recruiting
NCT07452601 2026-03-05
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT06452602 2026-02-27
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT07437898 2026-02-27
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
The Affiliated Hospital of Putian University
Phase 2 Recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07376876 2026-01-29
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT07374003 2026-01-28
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05978193 2026-01-22
SCR-ESCC-01
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07290010 2025-12-17
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT07272291 2025-12-09
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07266493 2025-12-05
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06912074 2025-11-17
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07086469 2025-11-17
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06143748 2025-09-17
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07152678 2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06509568 2025-08-29
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT07128693 2025-08-19
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06356688 2025-08-08
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03320629 2025-08-06
A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Terminated
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT07049185 2025-07-03
QICE-ESCC
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06165380 2025-06-26
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT07016724 2025-06-12
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT06446726 2025-06-06
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04666090 2025-05-15
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06885814 2025-03-20
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT04212598 2024-12-10
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Wuhan University
Phase 2 Completed
NCT06603402 2024-12-03
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Sichuan University
Phase 2 Recruiting
NCT06329869 2024-12-02
SG-ESCC
National Taiwan University Hospital
Phase 2 Recruiting